

CITATION REPORT

List of articles citing

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

DOI: 10.1016/s2213-8587(17)30309-1

Lancet Diabetes and Endocrinology, the, 2017, 5, 877-886.

Source: <https://exaly.com/paper-pdf/67022626/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
204	Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 843-845	18.1	2
203	The impact of glucose-lowering medications on cardiovascular disease. 2018 , 7, 13-17		
202	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. 2017 , 2017, 9257930		0
201	Updates on cardiovascular outcome trials in diabetes. 2017 , 16, 128		36
200	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2018 , 81, 189-222		14
199	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. 2018 , 20, 853-872		264
198	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073		20
197	Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. 2018 , 47, 33-50		77
196	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. 2018 , 47, 117-135		16
195	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. 2018 , 41, 14-31		263
194	Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials. 2018 , 14, 67-68		1
193	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. 2018 , 78, 203-214		5
192	Precision medicine in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 891-900	18.1	60
191	Treatment with Oral Drugs. 2018 , 1-44		
190	Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. 2018 , 12, CD005061		17
189	Treatment approach to type 2 diabetes: Past, present and future. 2018 , 9, 209-219		32
188	GOALS FOR MEDICAL TREATMENT IN OBESITY AND PREDIABETES: IMPROVING OUTCOMES FOR BOTH. 2018 , 24, 1093-1098		0

187	Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm". 2018 , 78, 1567-1592	1
186	Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. 2018 , 103, 3611-3619	18
185	Evidence-Based Management of Diabetes in Older Adults. 2018 , 35, 1065-1078	11
184	Treatment with Oral Drugs. 2018 , 527-569	
183	Hypoglycemic Efficacy of Docking Selected Natural Compounds against α -Glucosidase and α -Amylase. 2018 , 23,	19
182	What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?. 2018 , 10, 683-685	3
181	Relative contributions of preprandial and postprandial glucose exposures, glycemic variability, and non-glycemic factors to HbA in individuals with and without diabetes. 2018 , 8, 38	17
180	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. 2018 , 41, 1590-1599	11
179	2020 vision - An overview of prospects for diabetes management and prevention in the next decade. 2018 , 143, 101-112	22
178	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2018 , 431-454	2
177	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. 2018 , 33, 197-210	2
176	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. 2018 , 18, 64	19
175	Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. 2018 , 17, 20	28
174	Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2018 , 17, 30	15
173	Treatment: Alpha Glucosidase Inhibitors. 2019 , 238-244	1
172	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. 2019 , 21, 3-14	29
171	Prediabetes: lifestyle, pharmacotherapy or regulation?. 2019 , 10, 2042018819863020	5
170	Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. 2019 , 62, 1319-1328	24

169	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. 2019 , 18, 135	6
168	Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. 2019 , 20, 2229-2235	37
167	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. 2019 , 132, S13-S20	1
166	Isolation and Characterization of Antihyperglycemic Compounds from <i>Vigna angularis</i> Extracts. 2019 , 84, 3172-3178	2
165	Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset. 2019 , 9, 1657756	9
164	Diabetes prevention and cardiovascular complications. 2019 , 62, 2161-2162	4
163	Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. 2019 , 11, 80	21
162	Management of diabetes mellitus in patients undergoing liver transplantation. 2019 , 141, 556-573	14
161	Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention. 2019 , 94, 287-308	24
160	Examining the results of cardiovascular outcome trials. 2019 , 30, 87-90	
159	Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. 2019 , 42, 1136-1146	7
158	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. 2019 , 12, 447-455	9
157	Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. 2019 , 21, 1661-1667	14
156	Heart failure and diabetes: management and open issues. 2019 , 44, 203-209	1
155	[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)]. 2019 , 131, 27-38	4
154	Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. 2019 , 35, 1529-1534	14
153	Aim to normalize glucose levels and reduce cardiovascular mortality when managing type 2 diabetes in the elderly. 2019 , 35, 271-277	
152	Impact des nouvelles classes d'antidiabétiques sur le risque cardiovasculaire dans le diabète de type 2. 2019 , 13, 42-49	1

151	Evidence-Based Cardiovascular Risk Management in Diabetes. 2019 , 19, 439-448	5
150	Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance. 2019 , 15, 127-133	3
149	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. 2019 , 21, 1277-1290	43
148	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. 2019 , 79, 231-242	8
147	Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease. 2019 , 37, 250-259	3
146	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA) sowie der Deutschen Gesellschaft für Interventionelle Radiologie (DIR)]. 2019 , 11, 3253-3261	0
145	Anti-diabetic agents for prevention of type 2 diabetes mellitus in people with pre-diabetes: a systematic review and network meta-analysis protocol. 2019 , 9, e029073	2
144	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. 2019 , 124 Suppl 1, S12-S19	8
143	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. 2019 , 127, S105-S113	3
142	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. 2019 , 26, 73-80	39
141	Targets for blood glucose: What have the trials told us. 2019 , 26, 64-72	6
140	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. 2019 , 20,	7
139	Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. 2019 , 19, 154	3
138	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. 2019 , 40, 2907-2919	22
137	Glucose Variability and Coronary Artery Disease. 2019 , 28, 553-559	20
136	Non-traditional risk factors for coronary calcification and its progression in patients with type 2 diabetes: The impact of postprandial glycemia and fetuin-A. 2019 , 47, 846-858	3
135	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. 2019 , 19, 121-127	6
134	Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. 2019 , 45, 110-121	31

133	Update on postprandial hyperglycaemia: the pathophysiology, prevalence, consequences and implications of treating diabetes. 2020 , 220, 57-68	1
132	Update on postprandial hyperglycemia: The pathophysiology, prevalence, consequences and implications of treating diabetes. 2020 , 220, 57-68	1
131	Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients. 2020 , 27, 1352-1364	3
130	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2020 , 41, 255-323	1360
129	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2020 , 16, 65-73	
128	:"""". 2020 , 78, 67-76	
127	Evaluation of the value of diabetes risk scores in screening for undiagnosed diabetes and prediabetes: a community-based study in southwestern China. 2020 , 132, 737-745	0
126	Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes. 2020 , 16, 441-456	6
125	Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. 2020 , 43, 1958-1966	9
124	Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. 2020 , 6, 313-323	12
123	Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin. 2020 , 13,	1
122	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. 2021 , 396, 2019-2082	90
121	New insights into the older hypoglycemic agents in type 2 diabetes therapy. 2020 , 12, 844-847	
120	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. 2020 , 40, 1-122	8
119	Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity. 2020 , 78, 69-77	24
118	Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. 2020 , 17, e1003316	5
117	Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. 2020 , 21,	6
116	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. 2020 , 170, 108488	3

115	Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota. 2020 , 10, 530160		5
114	Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). 2020 , 73, 404.e1-404.e59		2
113	Stroke in the patient with diabetes (Part 2) - Prevention and the effects of glucose lowering therapies. 2020 , 164, 108199		1
112	Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes. 2020 , 67, 877-881		5
111	Glucose lowering and pancreato-protective effects of Abrus Precatorius (L.) leaf extract in normoglycemic and STZ/Nicotinamide - Induced diabetic rats. 2020 , 258, 112918		9
110	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 418-435	18.1	59
109	Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans. 2020 , 9, e2000057		0
108	Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone. 2020 , 11, 658-667		10
107	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. 2020 , 21, 1565-1578		7
106	Pleiotropic effects of anti-diabetic drugs: A comprehensive review. 2020 , 884, 173349		5
105	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2020 , 83, 587-621		3
104	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. 2020 , 43, 2242-2247		4
103	A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study. 2020 , 15, e0234237		0
102	Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 192-205	18.1	49
101	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. 2021 , 1307, 129-152		13
100	Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. 2020 , 15, e0231196		11
99	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. 2021 , 15, 31-51		13
98	Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study. 2021 , 172, 108489		1

97	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. 2020 , 11, 612722	2
96	In-vitro antioxidant and antidiabetic activity of Curcuma xanthorrhiza. 2021 ,	1
95	Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes. 2021 , 21, 25	4
94	Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis. 2021 , 11, 11	5
93	Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs. 2021 , 22,	2
92	Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance. 2021 , 13, 817-826	0
91	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2021 , 17, 283-292	1
90	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. 2021 , 384, 1248-1260	22
89	Diabetic heart disease: A clinical update. 2021 , 12, 383-406	4
88	Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial. 2021 , 44, 1324-1333	6
87	Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. 2021 , 9,	2
86	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. 2021 , 12, 670155	10
85	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). 2021 , 6-61	2
84	Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis. 2021 , 12, 679456	3
83	Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study. 2021 , 18, e1003692	1
82	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. 2021 , 23, 75	3
81	Predicting Long-Term Mortality in Patients with Angina across the Spectrum of Dysglycemia: A Machine Learning Approach. 2021 , 11,	
80	CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. 2021 ,	5

79	Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials. 2021 , 374, n1651	11
78	Network Meta-analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance. 2021 , 43, 1524-1556	1
77	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. 2021 , 47, 101272	5
76	Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs - A systematic review. 2021 ,	
75	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. 2021 , 17, e618-e630	0
74	Antidiabetika. 2019 , 471-490	1
73	ESVM Guideline on peripheral arterial disease. 2019 , 48, 1-79	46
72	5 Conservative treatment for PAD - Risk factor management. 2019 , 48, 1-12	6
71	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen	0
70	Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development. 2021 , 30, 85-93	3
69	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. 2019 , 83-91	8
68	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. 2021 , 44, 586-594	24
67	SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins. 2019 , 23, 175-183	2
66	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. 2020 , 24, 1-122	33
65	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. 2019 , 113, 787-891	29
64	Anestesia y diabetes en el perioperatorio. 2021 , 66, 195-204	
63	Rodent diet aids and the fallacy of caloric restriction. 2021 , 200, 111584	0
62	Robust estimates of heritable coronary disease risk in individuals with type 2 diabetes. 2021 ,	1

- 61 Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG). **2021**, 16, S351-S361 0
- 60 Diabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires. **2017**, 201, 1209-1225
- 59 Antidiabetika. **2018**, 353-368
- 58 Mechanisms of cardiovascular protection of non-insulin antidiabetic medications. **2018**, 21, 376-385
- 57 Association of myeloperoxidase, homocysteine and high-sensitivity C-reactive protein with the severity of coronary artery disease and their diagnostic and prognostic value. **2020**, 20, 1532-1540 3
- 56 Antidiabetika. **2020**, 339-358
- 55 Choosing Medications for Type 2 Diabetes [What Weighting Should Be Given to Cardiovascular Risk Reduction?]. **2021**, 174-186
- 54 [B Prediabetes a Risk Factor or Is It a Disease?]. **2021**, 1-16
- 53 Cardiovascular outcomes and safety with antidiabetic drugs. **2018**, 12, 70-83 5
- 52 Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article.. **2021**, 13, e19398 0
- 51 Glycaemic Control in Diabetes. **2021**, 47
- 50 Antidiabetika. **2021**, 241-260
- 49 Repeated glucose spikes and insulin resistance synergistically deteriorate endothelial function and bardoxolone methyl ameliorates endothelial dysfunction.. **2022**, 17, e0263080 1
- 48 Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.. **2021**, e14780 1
- 47 A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes.. **2022**, 2022, 2971382 0
- 46 Flavonoid constituents of Crevost et Lemarie and their antioxidant and antidiabetic effects in diabetic rats - and studies.. **2021**, 0
- 45 Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin, and inadequately controlled with metformin monotherapy or drug naive: a multicenter, randomized, open-label, prospective study (ACADEMIC).. **2022**,
- 44 Oral Therapies for Type 2 Diabetes. **2022**, 325-334

43	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.. 2022,	0
42	Review of non-insulin antidiabetic pharmacotherapy in patients with heart failure diabetes mellitus in the Czech Republic in 2018. 2022, 64, 20-24	0
41	Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization.. 2022, e13596	1
40	Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.. 2022, 13, 818537	0
39	Health-related quality of life for normal glycaemia, prediabetes and type 2 diabetes mellitus: Cross-sectional analysis of the ADDITION-PRO study.. 2022, e14825	0
38	Molecular Mechanism for the αGlucosidase Inhibitory Effect of Wheat Germ Peptides. 2021,	3
37	The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies.. 2021, 12, 782391	5
36	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus.. 2022,	
35	Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations.. 2022,	1
34	Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.	7
33	Comparison of Bone Mineral Density in US Adults With Diabetes, Prediabetes and Normoglycemia From 2005 to 2018. 2022, 13,	1
32	Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence From Randomized Controlled Trials and Clinical Perspective. 2022, 14, 1180	
31	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2022, 18, 402-411	
30	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.	0
29	Landscape of cardiometabolic risk factors in Chinese population: a narrative review. 2022, 21,	0
28	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.	0
27	Predict the Chances of Heart Abnormality in Diabetic Patients Through Machine Learning. 2022, 4, 61-76	
26	Acarbose and Alpha Glucosidase Inhibitors. 2022, 229-238	

25	Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial. 2022 , 14, 455-464	0
24	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,	8
23	Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. 2022 , 11, 4660	0
22	Herz und Diabetes. 2022 , 1-14	0
21	Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study. 2022 , 21,	0
20	Diabetes and cardiovascular risk according to gender: an overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. 2022 ,	0
19	Effect of oats and oat β -glucan on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials. 2022 , 10, e002784	0
18	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßmedizin und Gefäßdiagnostik (DGG)]. 2022 , 17, 5354-5364	0
17	Carbohydrate quality and cardiovascular disease: Need for trials. 2022 ,	0
16	Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults with Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.	0
15	Pharmacotherapy of type 2 diabetes: An update and future directions. 2022 , 137, 155332	3
14	Transition metal complexes of imidazole derived Schiff bases: Antioxidant/anti-inflammatory/antimicrobial/enzyme inhibition and cytotoxicity properties. 2023 , 1274, 134384	0
13	Synthesis, biological evaluation and molecular docking study of benzimidazole derivatives as α -glucosidase inhibitors and anti-diabetes candidates. 2023 , 1276, 134774	0
12	Comparison of the generation of α -glucosidase inhibitory peptides derived from prolamins of raw and cooked foxtail millet: In vitro activity, de novo sequencing, and in silico docking. 2023 , 135378	1
11	ANTIDIABETIC ACTIVITY OF NOVEL CHROMENE COMPOUND ISOLATED FROM PEPEROMIA PELLUCIDA L. KUNTH AND IN SILICO STUDY AGAINST DPP-IV, ALPHA-GLUCOSIDASE, ALPHA-AMYLASE, AND ALDOSE REDUCTASE FOR BLOOD GLUCOSE HOMEOSTASIS. 110-116	0
10	Diabetes mellitus. 2022 , 267-285	0
9	Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. 2023 , 100056	1
8	Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes. 14,	0

- 7 Long-term effects of lowering postprandial glucose level on cardiovascular outcomes in early-stage diabetic patients with coronary artery disease: 10-year post-trial follow-up analysis of the DIANA study. **2023**, 37, 108469 ○
- 6 Identification and Molecular Binding Mechanism of Novel α-Glucosidase Inhibitory Peptides from Hot-Pressed Peanut Meal Protein Hydrolysates. **2023**, 12, 663 ○
- 5 A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes. **2023**, 14, 749-766 ○
- 4 Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial. **2023**, 12, 2035 ○
- 3 Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. **2023**, 22, ○
- 2 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 1 Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024 ○